Abstract
Background After the first case of COVID-19 in Japan on 15 January 2020, multiple nationwide COVID-19 clusters were identified by the end of February. The Japanese government focused on mitigating emerging COVID-19 clusters by conducting active nationwide epidemiological surveillance. However, an increasing number of cases appeared until early April, many with unclear infection routes exhibiting no recent history of travel outside Japan. We aimed to evaluate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome sequences from COVID-19 cases until early April and characterise the genealogical networks to demonstrate possible routes of spread in Japan.
Methods Nasopharyngeal specimens were collected from patients and a quantitative reverse transcription polymerase chain reaction testing for SARS-CoV-2 was performed. Positive RNA samples were subjected whole genome sequencing and a haplotype network analysis was performed.
Findings Some of the primary clusters identified during January and February in Japan directly descended from Wuhan-Hu-1-related isolates in China and other distinct clusters. Clusters were almost contained until mid-March; the haplotype network analysis demonstrated that COVID-19 cases from late March through early April may have caused an additional large cluster related to the outbreak in Europe, leading to additional spread within Japan. National self-restraint during February was effective in mitigating the COVID-19 spread, but late action on stopping immigration and declaring national emergency in Japan might be involved in the later increase in cases.
Interpretation Genome surveillance suggested that at least two distinct SARS-CoV-2 introductions from China and other countries occurred.
Funding Japan Agency for Medical Research and Development.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is not a clinical trial. Not available.
Clinical Protocols
https://www.gisaid.org/epiflu-applications/next-hcov-19-app/
Funding Statement
This study was supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant number JP20fk0108103, JP19fk0108103 and JP19fk0108104.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the National Institute of Infectious Diseases in Japan (Approval No. 1091). It was conducted according to the principles of the Declaration of Helsinki, in compliance with the Law Concerning the Prevention of Infections and Medical Care for Patients of Infections of Japan. The ethical committee waived the need for written consent since the study involved the viral genome sequencing. The personal data related to the clinical information were anonymised, and our procedure is to not request written consent for all patients with COVID-19.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The new sequences have been deposited in Global Initiative on Sharing All Influenza Data (GISAID) with accession IDs EPI_ISL_479792 to EPI_ISL_480227 (Table S2).
https://www.gisaid.org/epiflu-applications/next-hcov-19-app/
